๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 14 Chengdu 12 Beijing 9 Wuhan 6
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai18 Guangzhou14 Chengdu12 Beijing9 Wuhan6
All 33 locations
Target enrolment
to

Trials with a site in Shanghai

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
NCT07254585Head and Neck Squamous Cell Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
70
Shanghai
2025-12-18
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
NCT07105592Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 1/2
68
Shanghai
2025-05-13
Recruiting
PDO Based Drug Sensitive Test in R/M HNSCC
NCT06686342Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro
Huashan Hospital
Observational
100
Shanghai
2025-03-26
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Not yet open
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06814067Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Fudan University
Phase 2
80
Shanghai
2025-02-10
Active, closed
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06668961Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
48
Shanghai
2024-11-07
Recruiting
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
NCT06194656Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products
Phase 2
81
Shanghai
2024-09-27
Recruiting
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
NCT06494995Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
52
Shanghai
2024-07-03
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
NCT06081673Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-30
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06006169Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Active, closed
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Active, closed
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04843098Head and Neck Squamous Cell Carcinoma
Suzhou Junde Biotechnology Co., Ltd
Phase 1/2
108
Shanghai
2021-05-26
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

12 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 18 studies
PhaseStudiesRecruitingShare
Phase 212766.7%
Phase 1/23216.7%
Phase 12211.1%
Observational115.6%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.52
Fudan University43
CSPC Megalith Biopharmaceutical Co.,Ltd.11
Gilead Sciences10
HRYZ Biotech Co.11
Huashan Hospital11
Jiangsu Simcere Pharmaceutical Co., Ltd.11
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine11
Shanghai Institute Of Biological Products11
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.